ClinicalTrials.gg
CompletedNCT00125164Updated Sep 18, 2019Results posted

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

A Phase 3 interventional study of rhIGF-1 (mecasermin, Tercica, Inc.) in Growth Disorders and Insulin-Like Growth Factor-1 Deficiency, sponsored by Ipsen. Completed at 1 site in United States. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Growth Disorders with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Growth Disorders · United States.

Enrollment
5th of 17
137 · median 50
Started
2004
with 1 other
Phase 3
4 of 25
1 open now
Registered
3rd of 25
by date
Lead sponsor
2 of 25
Ipsen

Among the 25 studies in Growth Disorders with a site in United States, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2004, is one of 4 in phase 3, and was the 3rd registered.

Growth Disorders

227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.

Browse Growth Disorders studies →

Open to participants now

4 of the 25 studies in Growth Disorders with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Growth Disorders studies recruiting now, 3 (17%) set no upper age limit and 13 (72%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Growth Disorders with a site in United States, or all of them as a file.
02

Study summary

This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature associated with low IGF-1 levels but who produce sufficient growth hormone (GH). Subjects will be randomized to either an observation arm or to active treatment.

Read the detailed description

Prepubertal growth failure associated with primary IGF-1 deficiency (IGFD). Primary IGFD is a term that has been used to describe patients with intrinsic cellular defects in GH action. In this protocol, primary IGFD is defined as short stature (height standard deviation score[SDS]\<-2 below the mean for age and gender), low serum IGF-1 (IGF-1 SDS \<-2 below the mean for age and gender), and levels of growth hormone (GH) that are normal (≥7ng/mL) after a GH stimulation test. Primary IGFD is believed to result from a lower than normal ability to produce IGF-1 when exposed to normal levels of GH, i.e., a type of GH insensitivity or GH resistance.

This trial is one year, randomized, open label, observation-controlled, parallel-dose comparison efficacy and safety study conducted in approximately 40 centers across the United States.

03

Conditions studied

  • Growth Disorders
  • Insulin-Like Growth Factor-1 Deficiency

Browse trials for

Keywords

  • Primary IGF-1 Deficiency
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronological age ≥ 3 and chronological or bone age less than or equal to 11 years inclusive in girls;
  • Chronological age ≥ 3 and chronological or bone age less than or equal to 12 years inclusive for boys
  • Prepubertal
  • Height SD score of \< -2
  • IGF-1 SD score of \< -2

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with rhGH, rhIGF-1, or other growth-influencing medications
  • Growth failure associated with other identifiable causes (e.g., syndromes, chromosomal abnormality)
  • Chronic illness such as diabetes, cystic fibrosis, etc.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • No intervention
    Untreated

    Observational Group

  • Experimental
    40 μg/kg BID (twice daily dosing)

    Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.

    Drug: rhIGF-1 (mecasermin, Tercica, Inc.)

  • Experimental
    80 μg/kg BID (twice daily dosing)

    Injection of rhIGF-1 80 μg/kg BID

    Drug: rhIGF-1 (mecasermin, Tercica, Inc.)

  • Experimental
    120 μg/kg BID (twice daily dosing)

    Injection of rhIGF-1 120 μg/kg BID

    Drug: rhIGF-1 (mecasermin, Tercica, Inc.)

Interventions

06

What researchers measure

Primary outcomes

  1. Height Velocity During the First Year - Intent to Treat (ITT)Population

    Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.

    Time frame: Measured at baseline and at one year

Secondary outcomes

  1. Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population

    Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.

    Time frame: Measured at baseline and at one year

  2. Changes in Bone Age From Baseline to One Year

    Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.

    Time frame: Measured at baseline and at one year

  3. Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year

    Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.

    Time frame: Measured at baseline and at one year

  4. Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year

    Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.

    Time frame: Measured at baseline and at one year

  5. Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year

    Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.

    Time frame: Measured at baseline and at one year

  6. Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year

    Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.

    Time frame: Measured at baseline and at one year

  7. IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)

    Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.

    Time frame: Study Day 1 and Day 7

  8. IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)

    Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.

    Time frame: Study Day 1 and Day 7

07

Results

Posted Apr 30, 2010

Participant flow

Study Initiation Date: 14 March 2004. Study completion Date: 02 July 2008. 44 investigators screened subjects; 14 did not enroll any subjects. 137 subjects were enrolled. Consent for one randomized subject was withdrawn prior to any study measurements. This subject was excluded from all analyses.

Participant flow — Overall Study
MilestoneUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Started25164451
Completed23164045
Not completed2046
Withdrew: Adverse event0024
Withdrew: Lost to follow-up0011
Withdrew: Withdrawal by subject2011

Outcome measures

PrimaryHeight Velocity During the First Year - Intent to Treat (ITT)Population

Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · cm/yr
Height Velocity During the First Year - Intent to Treat (ITT)Population
cm/yrUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Height Velocity During the First Year - Intent to Treat (ITT)Population5.2 ± 1.0—6.9 ± 1.07.7 ± 1.5
Statistical analysis
  • Untreated vs 80 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = <0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 1.79 · 95% CI 1.19 to 2.39
  • Untreated vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = < 0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 2.58 · 95% CI 1.99 to 3.16
  • 80 μg/kg BID (Twice Daily Dosing) vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = 0.0032 · Ls mean difference: 0.79 · 95% CI 0.27 to 1.31
SecondaryChange From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population

Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · SD/year
Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population
SD/yearUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population0.02 ± 0.24—0.38 ± 0.170.48 ± 0.32
Statistical analysis
  • Untreated vs 80 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = < 0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 0.37 · 95% CI 0.24 to 0.50
  • Untreated vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = < 0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 0.47 · 95% CI 0.34 to 0.60
  • 80 μg/kg BID (Twice Daily Dosing) vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = 0.0495 · Ls mean difference: 0.11 · 95% CI 0.00 to 0.22
SecondaryChanges in Bone Age From Baseline to One Year

Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · Year
Changes in Bone Age From Baseline to One Year
YearUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Changes in Bone Age From Baseline to One Year0.8 ± 0.3—1.1 ± 0.41.2 ± 0.5
SecondaryPercent Changes From Baseline in Serum Concentrations of IGF-1 at One Year

Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · Percent change
Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year
Percent changeUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year64 ± 120—227 ± 220266 ± 215
SecondaryPercent Changes From Baseline in Serum Concentrations of IGF-2 at One Year

Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · Percent change
Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year
Percent changeUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year14 ± 28—-38 ± 37-37 ± 32
SecondaryPercent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year

Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · Percent change
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year
Percent changeUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year-16 ± 26—58 ± 8461 ± 79
SecondaryPercent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year

Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.

Time frame:
Measured at baseline and at one year
Reported as:
Mean · Percent change
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year
Percent changeUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year13 ± 33—-19 ± 22-19 ± 28
SecondaryIGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)

Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.

Time frame:
Study Day 1 and Day 7
Reported as:
Mean · ng/mL
IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)
ng/mLUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)40 ± 49—53 ± 4948 ± 43
SecondaryIGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)

Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.

Time frame:
Study Day 1 and Day 7
Reported as:
Mean · mg/dL
IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)
mg/dLUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH)744 ± 459—800 ± 1095681 ± 568
Post-hocHeight Velocity During the First Year for Subjects - Completers

Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.

Time frame:
One Year
Reported as:
Mean · cm/year
Height Velocity During the First Year for Subjects - Completers
cm/yearUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Height Velocity During the First Year for Subjects - Completers5.2 ± 1.0—7.0 ± 1.07.9 ± 1.4
Statistical analysis
  • Untreated vs 80 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = <0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 1.83 · 95% CI 1.26 to 2.40
  • Untreated vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = <0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 2.83 · 95% CI 2.26 to 3.39
  • 80 μg/kg BID (Twice Daily Dosing) vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = 0.0002 · Ls mean difference: 1.01 · 95% CI 0.50 to 1.51
Post-hocChange From Baseline in Height Standard Deviation (SD) Score at One Year - Completers

Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.

Time frame:
One Year
Reported as:
Mean · SD/year
Change From Baseline in Height Standard Deviation (SD) Score at One Year - Completers
SD/yearUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
Change From Baseline in Height Standard Deviation (SD) Score at One Year - Completers0.02 ± 0.24—0.39 ± 0.170.53 ± 0.30
Statistical analysis
  • Untreated vs 80 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = <0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 0.37 · 95% CI 0.25 to 0.50
  • Untreated vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = <0.0001 (The two-sided p-values for the comparisons are adjusted for multiple comparisons using Dunnett's method.) · Ls mean difference: 0.52 · 95% CI 0.39 to 0.64
  • 80 μg/kg BID (Twice Daily Dosing) vs 120 μg/kg BID (Twice Daily Dosing) · ANCOVA · p = 0.0071 · Ls mean difference: 0.15 · 95% CI 0.04 to 0.26

Adverse events

Collected over Adverse events were collected until 30 days after last subject visit or until resolution. Adverse event collection for an individual subject was 1 year 1 month. Across study adverse event reporting continued for a total of 4 years 5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Untreated—1/25 (4%)18/25 (72%)
40 μg/kg BID (Twice Daily Dosing)—1/16 (6.3%)16/16 (100%)
80 μg/kg BID (Twice Daily Dosing)—2/44 (4.5%)37/44 (84.1%)
120 μg/kg BID (Twice Daily Dosing)—5/51 (9.8%)43/51 (84.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
GastroenteritisGastrointestinal disorders0/251/160/440/51
VomitingGastrointestinal disorders0/251/160/440/51
CellulitisInfections and infestations1/250/160/440/51
Gastroenteritis escherichia coliGastrointestinal disorders0/250/161/440/51
Intracranial pressure increasedNervous system disorders0/250/161/440/51
Cor TriatriatumCongenital, familial and genetic disorders0/250/160/441/51
Hypoglycemic seizureEndocrine disorders0/250/160/441/51
Gastroenteritis viralInfections and infestations0/250/160/441/51
PneumoniaInfections and infestations0/250/160/441/51
DehydrationMetabolism and nutrition disorders0/250/160/441/51
Most frequent other events
Showing 10 of 19
Most frequent other events
EventUntreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)
HeadacheNervous system disorders4/258/1613/4421/51
CoughRespiratory, thoracic and mediastinal disorders4/254/1610/447/51
Nasal congestionRespiratory, thoracic and mediastinal disorders0/254/165/445/51
NauseaGastrointestinal disorders0/254/166/442/51
Upper respiratory tract infectionInfections and infestations6/253/1610/4412/51
Gastroenteritis viralInfections and infestations0/253/168/443/51
Injection site bruisingGeneral disorders0/253/166/444/51
Otitis mediaInfections and infestations3/253/162/444/51
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/253/164/444/51
GastroenteritisGastrointestinal disorders0/253/164/443/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Mean7.0 ± 2.47.6 ± 2.47.7 ± 2.47.6 ± 2.77.5 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Female10414836
Male15123043100
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Asian10124
Black00022
Hispanic204410
Native Hawaiian or Pacific Islander00011
White22163841117
Other00112
Stratum
Stratum(participants)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Height Standard Deviation Score < -2.6138253076
Height Standard Deviation Score >= -2.6128192160
Height Standard Deviation (SD) Score
Height Standard Deviation (SD) Score(SD)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Mean-2.8 ± 0.7-2.6 ± 0.6-2.7 ± 0.5-2.9 ± 0.8-2.8 ± 0.7
IGF-1 Standard Deviation (SD) Score
IGF-1 Standard Deviation (SD) Score(SD)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Mean-2.6 ± 0.7-2.8 ± 0.8-2.6 ± 0.7-3.0 ± 0.8-2.8 ± 0.8
Maximum Stimulated Growth Hormone
Maximum Stimulated Growth Hormone(ng/mL)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Mean17.0 ± 6.516.9 ± 6.217.8 ± 9.020.7 ± 16.818.6 ± 12.1
Weight
Weight(Kg)Untreated40 μg/kg BID (Twice Daily Dosing)80 μg/kg BID (Twice Daily Dosing)120 μg/kg BID (Twice Daily Dosing)Total
Mean17.8 ± 4.618.5 ± 4.719.4 ± 5.418.5 ± 5.718.6 ± 5.3
08

Study locations

1 site
  • Ipsen (formerly Tercica)
    Brisbane, California 94005, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2005
First posted
Jul 29, 2005
Start
Mar 2004
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Apr 30, 2010
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00125164
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Jul 29, 2005
Start date
Mar 2004
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Apr 30, 2010
Last update
Sep 18, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecasermin

Start the discussion